AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial

MEK inhibitor selumetinib improves progression-free survival in KRAS mutation-positive metastatic non-small cell lung cancer, hitting secondary endpoints. But the drug missed the overall survival primary endpoint.